anti cancer medicine

Nitnib 50mg Capsule (Sunitinib): High-Potency Targeted Therapy for Advanced Oncology. Nitnib 50mg Capsule is a maximum-strength, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Nitnib is a cornerstone in modern precision oncology. Manufactured by Sun Pharma, a global leader in high-quality pharmaceuticals, it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 50mg strength is the standard therapeutic dose used to achieve profound tumor suppression in aggressive cancers. Therapeutic Indications and Global Clinical Usage Nitnib 50 mg is a preferred therapeutic agent in international oncology protocols for: Renal Cell Carcinoma (RCC): Indicated as a first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Used for patients with GIST after disease progression on or intolerance to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Nitnib 50mg Works Nitnib 50 mg exerts its clinical effect by simultaneously targeting multiple receptors involved in tumor growth: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Signal Transduction Blockade: It targets various other tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Nitnib helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Standard Regimen (RCC/GIST): The typical clinical schedule involves 50 mg taken once daily for 4 weeks, followed by a 2-week rest period (the 4/2 cycle). Administration: Capsules must be swallowed whole with water; do not crush or chew. Consistency: It can be taken with or without food, but taking it at a consistent time each day is recommended to maintain steady-state plasma concentrations. Clinical Monitoring: Dosage may be modified by a healthcare professional based on individual patient response and toxicity levels. Safety Profile and Professional Monitoring Treatment with high-strength TKIs like Nitnib 50 mg, which requires consistent medical oversight: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Hypothyroidism is a common side effect; patients require regular thyroid-stimulating hormone (TSH) testing. Skin and Hair Changes: Patients may experience skin yellowing (discoloration), hair depigmentation, or hand-foot syndrome during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sugistran 50mg Capsule (Sunitinib): Targeted Multi-Kinase Therapy for Advanced Oncology Sugistran 50mg Capsule is a high-potency, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sugistran 50mg is a cornerstone in modern precision oncology. Manufactured by Zuventus Healthcare, it is specifically designed to interfere with the growth, signaling, and blood supply of malignant cells. The 50 mg strength is the standard therapeutic dose used to achieve profound tumor suppression in aggressive cancers. Therapeutic Indications and Global Clinical Usage Sugistran 50mg is a preferred therapeutic agent in international oncology protocols for: Renal Cell Carcinoma (RCC): Indicated as a first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Sugistran 50mg Works Sugistran 50mg employs a dual-action strategy to combat tumor progression by targeting various receptors on the surface of cancer cells and blood vessel cells: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid and uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sugistran helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Standard Regimen (RCC/GIST): The typical clinical schedule involves 50mg taken once daily for 4 weeks, followed by a 2-week rest period (the 4/2 cycle). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5mg or as adjusted) without a rest period. Administration: Capsules must be swallowed whole with water; do not crush or chew. Consistency: It can be taken with or without food, but taking it at a consistent time each day is recommended to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Treatment with high-strength TKIs like Sugistran 50mg, which requires consistent medical oversight: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing (discoloration), hair depigmentation, or hand-foot syndrome during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutinat 12.5mg Capsule (Sunitinib): Advanced Multi-Kinase Inhibition for Targeted Oncology. Sutinat 12.5 mg Capsule is a high-potency oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sutinat is a cornerstone in modern precision medicine. Manufactured by Natco Pharma Ltd., a global leader in high-quality oncology generics, it is engineered to disrupt the life cycle of cancer cells by blocking specific signaling pathways that promote tumor growth and vascularization. Therapeutic Indications and Clinical Usage Sutinat 12.5mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Indicated for the treatment of advanced or metastatic kidney cancer, often serving as a primary first-line therapy to improve progression-free survival. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: In specific clinical scenarios, it is used to reduce the risk of cancer returning after kidney surgery (nephrectomy) in high-risk patients. Mechanism of Action: How Sutinat 12.5mg Works Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By blocking these, it “starves“ the tumor by preventing the development of the new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutinat helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sutinat 12.5 mg is an oral medication. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): Typically involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5mg or as adjusted) without a rest period. Flexibility: The 12.5 mg strength allows for precise dose titration based on the patient’s clinical response and tolerance levels. Food Interaction: It can be taken with or without food but should be taken at a consistent time each day to maintain steady-state levels. Safety Profile and Clinical Monitoring Treatment with Sutinat 12.5 mg requires vigilant medical oversight for: Cardiovascular Health: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Monitoring for hypothyroidism is required, as this is a common side effect of TKI therapy. Liver & Heart Health: Periodic blood tests to check liver enzymes and heart function (LVEF) are standard during treatment. Skin Changes: Patients may experience skin discoloration (yellowing) or hair depigmentation during the treatment cycle. Storage and Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in their original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Svitinib 50mg Capsule (Sunitinib): High-Potency Targeted Therapy for Advanced Oncology. Svitinib 50mg Capsule is a maximum-strength, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. As a sophisticated multi-targeted receptor tyrosine kinase (RTK) inhibitor, the 50 mg dosage is the standard therapeutic strength used to achieve profound tumor suppression in aggressive cancers. Manufactured by Sun Pharma, Svitinib is engineered to disrupt the signaling pathways that allow cancer cells to grow, divide, and develop the blood supply necessary for tumor survival. Therapeutic Indications and Clinical Usage Svitinib 50mg is a cornerstone in international oncology protocols for: Advanced Renal Cell Carcinoma (RCC): Used as a first-line treatment for metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients with GIST after disease progression on or intolerance to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: Used in high-risk patients to prevent the recurrence of RCC following a nephrectomy. Mechanism of Action: How Svitinib 50mg Works Svitinib 50mg exerts its clinical effect by simultaneously targeting multiple receptors involved in tumor growth: Anti-Angiogenesis: It inhibits Vascular Endothelial Growth Factor Receptors (VEGFR) and Platelet-Derived Growth Factor Receptors (PDGFR). This “starves“ the tumor by preventing the formation of new blood vessels. Signal Transduction Blockade: It targets various other tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid, uncontrolled proliferation of malignant cells. Metastasis Inhibition: By disrupting these vital biological pathways, Svitinib helps limit the cancer's ability to invade surrounding tissues or spread to distant organs. Dosage and Administration Guidelines Standard Regimen (RCC/GIST): The typical clinical schedule involves 50 mg taken once daily for 4 weeks, followed by a 2-week rest period (the 4/2 cycle). Method of Administration: Capsules must be swallowed whole with water. They should not be crushed, opened, or chewed. Consistency: Can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Dose Adjustments: Based on individual patient tolerability, oncologists may adjust the dose to 37.5 mg or 25 mg using lower-strength capsules. Safety Profile and Professional Monitoring High-strength TKI therapy requires vigilant medical supervision to manage potential side effects: Cardiovascular Monitoring: Regular blood pressure checks are mandatory, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Hypothyroidism is a common side effect; patients require regular thyroid-stimulating hormone (TSH) testing. Skin and Hair Changes: Patients may experience skin discoloration (yellowing), hair depigmentation, or hand-foot syndrome. Liver and Heart Health: Periodic monitoring of liver enzymes and LVEF (heart function) is standard practice. Storage and Global Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Original Packaging: Keep capsules in the original container to protect them from moisture and light. Safety: Caregivers should handle the medication with care, avoid contact with broken capsules, and keep it out of reach of children. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutekast 50mg Capsule (Sunitinib): High-Potency Targeted Therapy for Advanced Malignancies. Sutekast 50 mg Capsule is a maximum-strength, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. As a sophisticated multi-targeted receptor tyrosine kinase (RTK) inhibitor, the 50 mg dosage is the standard therapeutic strength used to achieve profound tumor suppression in aggressive cancers. Manufactured by Aprazer Healthcare, Sutekast is engineered to disrupt the signaling pathways that allow cancer cells to grow, divide, and develop the blood supply necessary for tumor survival. Therapeutic Indications and Clinical Usage Sutekast 50 mg is a cornerstone in international oncology protocols for: Advanced Renal Cell Carcinoma (RCC): Used as a first-line treatment for metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients with GIST after disease progression on or intolerance to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: Used in high-risk patients to prevent the recurrence of RCC following a nephrectomy. Mechanism of Action: How Sutekast 50mg Works Sutekast 50 mg exerts its clinical effect by simultaneously targeting multiple receptors involved in tumor growth: Anti-Angiogenesis: It inhibits Vascular Endothelial Growth Factor Receptors (VEGFR) and Platelet-Derived Growth Factor Receptors (PDGFR). This “starves“ the tumor by preventing the formation of new blood vessels. Signal Transduction Blockade: It targets various other tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid, uncontrolled proliferation of malignant cells. Metastasis Inhibition: By disrupting these vital biological pathways, Sutekast helps limit the cancer's ability to invade surrounding tissues or spread to distant organs. Dosage and Administration Guidelines Standard Regimen (RCC/GIST): The typical clinical schedule involves 50 mg taken once daily for 4 weeks, followed by a 2-week rest period (the 4/2 cycle). Continuous Regimen (pNET): For pancreatic neuroendocrine tumors, a lower continuous daily dose (often 37.5 mg) may be derived from titration, though the 50 mg strength remains the baseline for many induction phases. Administration: Capsules must be swallowed whole with water. They should not be crushed, opened, or chewed. Consistency: Can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring High-strength TKI therapy requires vigilant medical supervision to manage potential side effects: Cardiovascular Monitoring: Regular blood pressure checks are mandatory, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Hypothyroidism is a common side effect; patients require regular thyroid-stimulating hormone (TSH) testing. Skin and Hair Changes: Patients may experience skin discoloration (yellowing), hair depigmentation, or hand-foot syndrome. Liver and Heart Health: Periodic monitoring of liver enzymes and LVEF (heart function) is standard practice. Storage and Global Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Original Packaging: Keep capsules in the original container to protect them from moisture and light. Safety: Caregivers should handle the medication with care, avoid contact with broken capsules, and keep out of reach of children. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Mitant 12.5mg Capsule (Sunitinib): Targeted Multi-Kinase Inhibition for Advanced Oncology Mitant 12.5 mg Capsule is a high-potency oral therapeutic agent containing the active substance Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Mitant is a cornerstone in modern targeted cancer therapy. Manufactured by Intas Pharmaceuticals Ltd., a global leader in high-quality oncology generics, it is designed to interfere with the growth and spread of cancer cells by blocking specific signaling pathways that promote tumor angiogenesis (blood vessel formation) and cellular proliferation. Therapeutic Indications and Clinical Usage Mitant 12.5 mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Indicated for the treatment of advanced or metastatic kidney cancer, often serving as a primary first-line therapy. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: In specific high-risk clinical scenarios, it is used to reduce the risk of cancer returning after kidney surgery (nephrectomy). Mechanism of Action: How Mitant 12.5mg Works Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By blocking these, it effectively “starves“ the tumor by preventing the development of the new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Mitant helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Mitant 12.5 mg is an oral medication. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): Typically involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose without a rest period. Flexibility: The 12.5 mg strength allows for precise dose titration (e.g., reaching 25 mg, 37.5 mg, or 50 mg) based on the patient’s clinical response and tolerance levels. Food Interaction: It can be taken with or without food but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Safety Profile and Clinical Monitoring Treatment with Mitant 12.5 mg requires vigilant medical oversight for: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Monitoring for hypothyroidism is required, as this is a common side effect of TKI therapy. Liver & Heart Health: Periodic blood tests to check liver enzymes and heart function (LVEF) are standard during treatment. Skin Changes: Patients may experience skin discoloration (yellowing) or hair depigmentation during the treatment cycle. Storage and Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in their original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Nitnib 12.5mg Capsule (Sunitinib): Targeted Multi-Kinase Therapy for Advanced Oncology Care Nitnib 12.5 mg Capsule is a high-efficacy, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Nitnib is a cornerstone in modern precision oncology. Manufactured by Sun Pharma, a global leader in high-quality pharmaceuticals, it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 12.5 mg strength allows for precise dose titration, ensuring that patients receive the optimal therapeutic benefit while managing systemic tolerability. Therapeutic Indications and Global Clinical Usage Nitnib 12.5 mg is a preferred therapeutic agent in international oncology protocols for: Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy. Mechanism of Action: How Nitnib 12.5mg Works Nitnib employs a dual-action strategy to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid and uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Nitnib helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Nitnib 12.5 mg is taken orally. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): The typical schedule involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5 mg or as adjusted) without a rest period. Flexibility: It can be taken with or without food, but consistency in timing is recommended to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing (discoloration) or hair depigmentation during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Rcnet 12.5mg Capsule (Sunitinib): Targeted Multi-Kinase Inhibition for Precision Oncology. Rcnet 12.5mg Capsule is a high-potency oral therapeutic agent featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Rcnet is a cornerstone in modern targeted cancer therapy. Manufactured by RPG Life Sciences, it is designed to interfere with the growth and spread of cancer cells by blocking specific signaling pathways that promote tumor angiogenesis (blood vessel formation) and cellular proliferation. Therapeutic Indications and Clinical Usage Rcnet 12.5mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Indicated for the treatment of advanced or metastatic kidney cancer, often serving as a primary first-line therapy. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment: In specific high-risk clinical scenarios, it is used to reduce the risk of cancer returning after kidney surgery (nephrectomy). Mechanism of Action: How Rcnet 12.5mg Works Rcnet works through a dual-mechanism approach to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By blocking these, it effectively “starves“ the tumor by preventing the development of the new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Rcnet helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Rcnet 12.5mg is an oral medication. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): Typically involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose without a rest period. Flexibility: The 12.5 mg strength allows for precise dose titration (e.g., reaching 25 mg, 37.5 mg, or 50 mg) based on the patient’s clinical response and tolerance levels. Food Interaction: It can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Safety Profile and Clinical Monitoring Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Monitoring for hypothyroidism is required, as this is a common side effect of TKI therapy. Liver & Heart Health: Periodic blood tests to check liver enzymes and heart function (LVEF) are standard during treatment. Skin Changes: Patients may experience skin discoloration (yellowing) or hair depigmentation during the treatment cycle. Storage and Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in their original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sugistran 12.5 mg Capsule (Sunitinib): Targeted Multi-Kinase Therapy for Advanced Oncology. Sugistran 12.5 mg Capsule is a high-potency, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sugistran is a cornerstone in modern precision oncology. Manufactured by Zuventus Healthcare, it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 12.5 mg strength allows for precise dose titration, ensuring that patients receive the optimal therapeutic benefit while managing systemic tolerability. Therapeutic Indications and Global Clinical Usage Sugistran 12.5 mg is a preferred therapeutic agent in international oncology protocols for: Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Sugistran 12.5mg Works Sugistran employs a dual-action strategy to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid and uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sugistran helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sugistran 12.5 mg is taken orally. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): The typical schedule involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5 mg or as adjusted) without a rest period. Flexibility: It can be taken with or without food, but consistency in timing is recommended to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing (discoloration) or hair depigmentation during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sunisam 12.5mg Capsule (Sunitinib): Targeted Therapy for Advanced Renal and Gastrointestinal Malignancies Sunisam 12.5 mg Capsule is a high-efficacy, oral antineoplastic medication containing Sunitinib as its active pharmaceutical ingredient. Manufactured by Samarth Life Sciences, Sunisam belongs to the class of drugs known as Tyrosine Kinase Inhibitors (TKIs). It is a multi-targeted therapy designed to inhibit the growth and spread of cancer cells by blocking specific enzymes that promote tumor proliferation and angiogenesis. The 12.5mg strength provides clinicians with the flexibility needed for precise dose adjustments based on individual patient tolerance and clinical response. Therapeutic Indications and Clinical Usage Sunisam 12.5mg is globally utilized in oncology for the treatment of several aggressive conditions: Advanced Renal Cell Carcinoma (RCC): Indicated as a primary treatment for metastatic kidney cancer to slow disease progression and improve survival outcomes. Gastrointestinal Stromal Tumors (GIST): Prescribed for patients whose disease has progressed or who are unable to tolerate imatinib mesylate therapy. Pancreatic Neuroendocrine Tumors (pNET): Used for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment for RCC: Used in specific clinical settings to reduce the risk of cancer recurrence in patients who have undergone a nephrectomy. Mechanism of Action: How Sunisam 12.5mg Works Sunisam disrupts the “fueling“ mechanisms of a tumor through a multi-targeted approach: Anti-Angiogenesis: It targets Vascular Endothelial Growth Factor Receptors (VEGFR) and Platelet-Derived Growth Factor Receptors (PDGFR). By blocking these signals, Sunisam prevents the tumor from developing the new blood vessels it needs for oxygen and nutrient supply. Inhibition of Proliferation: It targets other receptor tyrosine kinases (such as KIT and FLT3) that are responsible for the rapid and uncontrolled division of malignant cells. Metastasis Suppression: By interfering with these critical signaling pathways, the medication helps limit the cancer's ability to migrate and invade other parts of the body. Dosage and Administration Guidelines Method of Administration: Sunisam 12.5 mg should be taken orally. Capsules must be swallowed whole with water; do not open, crush, or chew them. Food Interaction: It can be taken with or without food, but taking it at a consistent time each day is recommended. Standard Regimen (RCC/GIST): Often follows a “4 weeks on, 2 weeks off“ schedule (the 4/2 cycle). Continuous Regimen (pNET): Generally administered as a continuous daily dose without a rest period. Clinical Monitoring: Dosage may be modified by a healthcare professional based on blood counts, blood pressure, and thyroid function tests. Safety Profile and Precautions Patients using Sunisam 12.5 mg should be under the regular supervision of an oncologist to monitor for: Cardiovascular Health: Monitoring for hypertension and changes in heart function (LVEF). Thyroid Function: Regular checks for hypothyroidism, a common side effect of TKI therapy. Hematological Stability: Periodic blood tests to check for neutropenia or thrombocytopenia. Dermatological Effects: Potential skin discoloration (yellowing), hair color changes, or hand-foot syndrome (blistering/redness on palms and soles). Wound Healing: Sunitinib may affect the body’s ability to heal wounds; treatment is usually paused before and after surgical procedures. Storage and Handling Temperature: Store at room temperature between 20°C and 25°C. Packaging: Keep capsules in their original container to protect them from light and moisture. Safety: Ensure the medication is kept out of reach of children and handled only by the prescribed patient or trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sunixar 12.5mg Capsule (Sunitinib): Targeted Multi-Kinase Therapy for Advanced Malignancies Sunixar 12.5 mg Capsule is a high-efficacy oral antineoplastic agent containing the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sunixar is a cornerstone in modern precision oncology. Manufactured by Beacon Pharmaceuticals, it is designed to interfere with the growth, signaling, and blood supply of cancer cells. The 12.5 mg strength allows for precise dose titration, ensuring that patients receive the optimal therapeutic benefit while managing systemic tolerability. Therapeutic Indications and Global Clinical Usage Sunixar 12.5 mg is a preferred therapeutic agent in international oncology protocols for: Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for advanced or metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients whose disease has progressed or who are intolerant to previous treatments like imatinib. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable or metastatic disease. Adjuvant Therapy: In certain regions, it is utilized to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Sunixar 12.5mg Works Sunixar employs a dual-action strategy to combat tumor progression: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid and uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sunixar helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sunixar 12.5 mg is taken orally. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): The typical schedule involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5 mg or as adjusted) without a rest period. Flexibility: It can be taken with or without food, but consistency in timing is recommended to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Treatment with Sunixar 12.5 mg requires consistent medical oversight to manage potential side effects: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib can cause hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing (discoloration) or hair depigmentation during the treatment cycle. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Sutekast 12.5mg Capsule (Sunitinib): Targeted Multi-Kinase Inhibition for Advanced Oncology Sutekast 12.5 mg Capsule is a potent, oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. It is a specialized multi-targeted receptor tyrosine kinase (RTK) inhibitor designed to disrupt the life cycle of cancer cells. Manufactured by Aprazer Healthcare, Sutekast 12.5 mg is a vital therapeutic intervention in modern precision medicine, specifically engineered to inhibit tumor growth and prevent the formation of blood vessels that nourish malignant cells. Therapeutic Indications and Clinical Usage Sutekast 12.5 mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Renal Cell Carcinoma (RCC): Indicated as a primary treatment for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumor (GIST): Used for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Specifically for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable or metastatic disease. Adjuvant Treatment: Utilized in certain high-risk scenarios to prevent cancer recurrence following a nephrectomy. Mechanism of Action: How Sutekast 12.5mg Works Sutekast works through a dual-action approach—inhibiting both tumor cell signaling and the tumor's blood supply: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). By blocking these, it “starves“ the tumor by preventing the development of the new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT and FLT3) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutekast helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sutekast 12.5 mg is an oral medication. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): The typical schedule involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5 mg or as adjusted) without a rest period. Flexibility: It can be taken with or without food but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Safety Profile and Professional Monitoring Treatment with Sutekast 12.5mg requires consistent medical oversight to manage potential side effects: Cardiovascular Health: Regular blood pressure monitoring is essential, as Sunitinib can cause hypertension. Hematological Checks: Periodic Complete Blood Counts (CBC) are required to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair: Patients may experience skin yellowing (discoloration) or hair depigmentation during the treatment cycle. Organ Function: Periodic monitoring of liver enzymes and heart function (LVEF) is standard practice. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C. Protection: Keep capsules in the original container to protect them from moisture and light. Safety: Ensure the medication is kept out of reach of children and handled only by the patient or a trained caregiver. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383